Market Place
Sourcing Support
Cytomx Therapeutics To Release Q1 2026 Financial Results On May 7
30 Apr 2026 //
GLOBENEWSWIRE
CytomX Announces Common Stock and Pre-Funded Warrant Offering
16 Mar 2026 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Q4, FY 2025 Results on March 16, 2026
04 Mar 2026 //
GLOBENEWSWIRE
Cytomx Therapeutics To Present At Upcoming February Conferences
04 Feb 2026 //
GLOBENEWSWIRE
CytomX Leases Floor at Wareham Development`s EmeryStation Campus
21 Jan 2026 //
BUSINESSWIRE
Cytomx Therapeutics To Present At December Investor Conferences
25 Nov 2025 //
GLOBENEWSWIRE
Cytomx Therapeutics To Release Q3 2025 Financial Results On Nov 6
30 Oct 2025 //
GLOBENEWSWIRE
CytomX Updates on CX-2051 Phase 1 Study
13 Aug 2025 //
GLOBENEWSWIRE
FDA cancels adcomm for Cabometyx in neuroendocrine tumors
10 Jan 2025 //
FIERCE PHARMA
CytomX lays off 40%, mulls future of Amgen-partnered drug
10 Jan 2025 //
FIERCE BIOTECH
CytomX Therapeutics to Present at Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
CytomX To Present At H.C. Wainwright Immune Cell Engager Virtual Conference
18 Jun 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Promotes Chris Ogden To Chief Financial Officer
17 Jun 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
22 May 2024 //
GLOBENEWSWIRE
CytomX shares plummet as Amgen-partnered cancer drug yields jumbled Phase 1 data
09 May 2024 //
ENDPTS
CytomX Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
CytomX Announces Nomination of Candidate in PROBODY TCB Collab with Astellas
03 Apr 2024 //
GLOBENEWSWIRE
CytomX Achieves $5M Astellas Milestone
03 Apr 2024 //
CONTRACT PHARMA
CytomX Announces Achievement in PROBODY® TCB Collaboration with Astellas
18 Mar 2024 //
GLOBENEWSWIRE
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
13 Mar 2024 //
FIERCE BIOTECH
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
11 Mar 2024 //
GLOBENEWSWIRE
CytomX to Report Fourth Quarter and Full Year 2023 Financial Results
04 Mar 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051
24 Jan 2024 //
GLOBENEWSWIRE
CytomX to Present at the B. Riley Securities Annual Oncology Conference
12 Jan 2024 //
GLOBENEWSWIRE
CytomX to Report Third Quarter 2023 Financial Results on November 7, 2023
31 Oct 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Announces New Employment Inducement Grants
20 Jul 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Announces $30 M Private Placement from BVF Partners L.P.
30 Jun 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Reports1Q 2023 FYR and Provides Business Update
09 May 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect at NASDAQ
25 Apr 2023 //
GLOBENEWSWIRE
AbbVie drops CytomX partnership, leaving PhII program in the air
29 Mar 2023 //
ENDPTS
CytomX Reports Full Year 2022 Financial Results and Provides Business Update
27 Mar 2023 //
GLOBENEWSWIRE
CytomX to Report Q4 and Full Year 2022 Financial Results on March 27, 2023
22 Mar 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming March Investor Conferences
28 Feb 2023 //
GLOBENEWSWIRE
Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference
28 Feb 2023 //
GLOBENEWSWIRE
CytomX Announces Milestone Achievement in Probody TCB Collaboration with Astellas
26 Jan 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the B. Riley Securities Investor Conference
17 Jan 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare
20 Dec 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Present Ph2 Data for Praluzatamab Ravtansine (CX-2009)
07 Dec 2022 //
GLOBENEWSWIRE
Regeneron swoops in with $2B biobucks pact for troubled CytomX
18 Nov 2022 //
FIERCEBIOTECH
CytomX Therapeutics Reports3Q 2022 Financial Results & Provides Update
08 Nov 2022 //
GLOBENEWSWIRE
CytomX to Present Preclinical for Conditionally Activated Interferon Alpha-2b
07 Nov 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming November Investor Conferences
02 Nov 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Report 3Q 2022 FYR on November 8, 2022
01 Nov 2022 //
GLOBENEWSWIRE
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody®
12 Sep 2022 //
GLOBENEWSWIRE
CytomX Therapeutics Presents Overview of Conditionally-Activated (ADC)
07 Sep 2022 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
03 Aug 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Report Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
CytomX lays off 40% as execs go back to drawing board, seek new deals
15 Jul 2022 //
ENDPTS
CytomX Therapeutics Provides Strategic Update
13 Jul 2022 //
GLOBENEWSWIRE
CytomX halts lead program; seeks partner as breast cancer drug disappoints
08 Jul 2022 //
ENDPTS
CytomX Tx Announces PII Results for Praluzatamab Ravtansine in Breast Cancer
06 Jul 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
CytomX Therapeutics Announces First Patient Dosed with CX-904 in PI Study
26 May 2022 //
GLOBENEWSWIRE
CytomX Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5
28 Apr 2022 //
GLOBENEWSWIRE
CytomX Tx Announces Retirement of John A. Scarlett from Board of Directors
14 Apr 2022 //
GLOBENEWSWIRE
CytomX Tx Announces Retirement of Frederick W. Gluck from Board of Directors
23 Mar 2022 //
GLOBENEWSWIRE
CytomX Tx to Present Updated PC Data for Activated Cytokine Program at AACR
17 Mar 2022 //
GLOBENEWSWIRE
